Move to topTop
TOKYO, JAPAN – February 9, 2023 – Terumo Corporation (TSE: 4543) today announced that it will revise the performance evaluation system for Executive Officers, effective from April 1, 2023*. This is part of Terumo’s continued effort to increase its corporate value through achieving the 5-Year Growth Strategy “GS26”.

Under GS26, Terumo is actively promoting sustainability management, and is strengthening its initiatives around ESG and Creating Social Value (CSV) as a means of increasing corporate value. 

The objective of the revision is to clarify the role and responsibilities of each individual Executive Officer in fulfilling the company’s commitment to sustainability management, while fairly evaluating their contribution to ESG and CSV.

Specifically, Terumo will be introducing “Future Corporate Value Targets” as a new performance evaluation index for Executive Officers, which will be reflected in their compensation. Future Corporate Value Targets will be set for each Executive Officer in line with the GS26 priority themes, including ESG and CSV. The achievement level of the targets will be evaluated by each owner of the GS26 priority themes, then authorized by the KPI Committee composed of Group Managing Executive Officers (GMEO) in Japan.

In April 2022, Terumo implemented a new management system for Executive Officers to enhance the Group's competitiveness on a global scale and to achieve GS26. With the new performance evaluation system taking place, Terumo will further strive towards GS26 and pursue growth globally.
*         The new system will be first applied to Executive Officers of Terumo Corporation in Japan. For Executive Officers outside of Japan, the company will implement measures in line with the new performance evaluation system from fiscal year 2023 considering compensation practices in each country.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.